COMMENTARY

Can “G1” Withdrawal Scheme Be Improved Enough to Serve Its Purpose?

By Takashi Ebisawa August 23, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

More than five years have passed since the rollout of the so-called “G1 withdrawal” scheme in the FY2018 drug pricing overhaul. As of April 2022, 267 long-listed products (LLPs) had been designated as G1 products, but withdrawals have been determined…

To read the full story

Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
August 23, 2023

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
TSE’s Growth Market Reform Puts Pressure on Biotechs
January 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…